Donohue syndrome is a rare congenital syndrome of insulin-resistance and abnormal glucose homeostasis, caused by mutations in the insulin receptor (INSR) gene. It is characterized by specific phenotypic and clinical features and the diagnosis is based on clinical, biochemical and genetic criteria.
Abstract:
Donohue syndrome is a rare congenital syndrome of insulin-resistance and abnormal glucose homeostasis, caused by mutations in the insulin receptor (INSR) gene. It is characterized by specific phenotypic and clinical features and the diagnosis is based on clinical, biochemical and genetic criteria.
We report two siblings with Donohue syndrome (cases 1, 2) with multiple clinical and biochemical characteristics. Both patients shared the same mutation and presented with intra-uterine growth restriction, failure to thrive, fasting hyperinsulinaemic hypoglycaemia and episodic post-prandial hyperglycaemia. Less common clinical features were also present, such as atrial septal defect and biventricular hypertrophy, clotting disorders, abnormal liver function tests and nephrocalcinosis. Interestingly, two previously unrecognized manifestations of the syndrome were also identified:
severe gastrointestinal dysmotility (case 1) and exocrine pancreatic insufficiency (case 2).
The co-existence of all the above clinical features makes these cases extremely rare.
Gastrointestinal dysmotility should always be considered as a potentially fatal feature in patients with the syndrome, due to the complexity of the possible co-morbidities.
In addition, our clinical experience for the first time suggests that pancreatic exocrine insufficiency may offer a possible explanation for the growth retardation observed in some patients with this syndrome. Our finding that replacement treatment with We report 2 siblings with Donohue syndrome who were observed to have additional clinical features (severe gastrointestinal dysmotility and pancreatic exocrine insufficiency) that have not been described previously.
Case reports
Here we report two cases of female infants with Donohue syndrome and highlight two additional clinical manifestations, which have not been reported previously ( Soon after birth she was noted to have pre-meal hypoglycaemia and post-feed hyperglycaemia. She had fasting insulin of >6945pmol/l and random insulin of 2634pmol/l and was started on Metformin. At the age of 3 months she was admitted to hospital with fever and was diagnosed with meningitis. At the age of 6 months, she was transferred to Great Ormond Street Hospital for multidisciplinary medical care.
The blood glucose concentrations ranged between 3-14mmol/L and serum insulin levels were >300mU/L when plasma glucose was 9mmol/L. Treatment with recombinant IGF-1 was started for the management of hyperglycaemia at the initial dose of 35mcg/kg/day to a final dose of 90mcg/kg/day. Good glucose control was achieved with only few hypoglycaemic episodes, which responded to feeds. As far as we are aware, this variant has not been reported before, which is consistent with a diagnosis of Donohue syndrome. Sequence analysis of DNA from both parents, confirmed that they are both heterozygous carriers of this variant, indicating that it was biparentallly inherited. The twin sibling possibly died of the same condition.
A cardiac echocardiogram revealed severe biventricular hypertrophy and secundum atrial septal defect (ASD) with moderate left to right shunt. The patient also had narrower right ear canal, as well as difficult airway, right-sided choanal atresia, small chest and required oxygen to maintain her saturation.
She subsequently developed abdominal distention and had a rectal biopsy.
Hirschsprung disease was excluded, but the cause of the abdominal distention remained undefined. She was also noted to have elevated liver enzymes without hepatosplenomegaly. Clotting abnormalities of unknown cause were also present, with low levels of factors II, VII, IX and XI. Vitamin K supplementation was started at the age of 6 months.
Medullary nephrocalcinosis with mild hydronephrosis and enlarged ovaries with multicystic appearances were identified on renal and pelvic USS, respectively.
Oestradiol and testosterone levels were raised. Significant failure to thrive and poor growth development, a typical clinical characteristic of Donohue syndrome, was also manifest, as shown in the growth chart (figure 1).
At the age of 7 months, the patient's abdomen became acutely distended and her clinical picture was indicative of abdominal obstruction. She underwent distal ileostomy, but because of difficult intubation, 3 days after surgery she developed seizures secondary to global hypoxic brain injury with infarction of the cerebral hemispheres. The life-limiting diffuse brain damage in combination with deteriorating abdominal distension, desaturations and stoma losses that required fluid resuscitation, led to her death at the age of 10 months.
Case 2: This is the 7th child of the same parents, sibling of case 1, and is now 10 months old. She was delivered at 38 +3 weeks of gestation by elective caesarean section and was small for gestational age, with a birth weight of 1.94 Kg (-3.52 SDS).
Soon after birth, she developed hypoglycaemia with blood glucose concentration of 1.9mmol/L, which resolved with intravenous fluid administration of 10% dextrose and, subsequently, total parenteral nutrition (TPN). She was also noted to have mild facial dysmorphism, microcephaly and was also markedly hirsute. Her phenotypic features were characteristic of Donohue syndrome. Intermittent abdominal distension with distended bowel loops was noted from birth and was referred to our hospital on day 9 of life. Growth retardation and poor weight gain were also present on maximum feed volume and calories (figure 1).
Another clinical finding was mildly deranged clotting, disturbed liver function tests and low factor II, VII, IX and XI levels (table 2) . Vitamin K1 and PIVKA-II (a functional marker of Vitamin K status) concentrations were undetectable.
On testing of her urine on the 21 st day of life, there was increased excretion of calcium, with raised urine calcium/creatinine ratio. The ultrasound of both kidneys showed bilateral nephrocalcinosis. Urine albumin to creatinine ratio was also raised (table 2) .
Moderate and severe pancreatic exocrine insufficiency was confirmed on two occasions (on day 49 and at 4 months of life, respectively) by abnormal pancreatic elastase-1 levels (table 2) . Fat globules were also present in the faeces. Vitamin K and Vitamin D levels were undetectable and supplementation of both vitamins was required. Since the pancreatic exocrine insufficiency was treated with pancreatic enzymes, our patient's weight gain has improved (figure 1).
Discussion
Most of our patients' clinical features have been previously described in literature. 
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